Axsome Therapeutics (AXSM) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $2.55.
- Axsome Therapeutics' Debt to Equity rose 2567.38% to $2.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.55, marking a year-over-year increase of 2567.38%. This contributed to the annual value of $3.31 for FY2024, which is 24316.27% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Debt to Equity is $2.55, which was up 2567.38% from $2.57 recorded in Q2 2025.
- Axsome Therapeutics' 5-year Debt to Equity high stood at $6.54 for Q2 2022, and its period low was $0.64 during Q3 2022.
- Its 4-year average for Debt to Equity is $2.15, with a median of $1.81 in 2024.
- As far as peak fluctuations go, Axsome Therapeutics' Debt to Equity crashed by 8995.52% in 2023, and later skyrocketed by 24316.27% in 2024.
- Axsome Therapeutics' Debt to Equity (Quarter) stood at $0.91 in 2022, then rose by 5.66% to $0.97 in 2023, then skyrocketed by 243.16% to $3.31 in 2024, then dropped by 23.22% to $2.55 in 2025.
- Its Debt to Equity was $2.55 in Q3 2025, compared to $2.57 in Q2 2025 and $3.57 in Q1 2025.